COMP <GO>
ENGN vs TVGN // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
enGene Therapeutics Inc. (NASDAQ) VS. Tevogen Inc. (NASDAQ) • 15-METRIC TALLY: ENGN 2
— TVGN 1
■ METRIC PARITY
LAST: $1.53 (0.00%) • MKT CAP: $102.5M
options-implied-move
—
LAST: $5.90 (-2.48%) • MKT CAP: $95.2M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENGN VS. TVGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENGN | TVGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -13.02% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | ENGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.0 | 37.1 | -0.14 | TVGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $102.5M | $95.2M | $7.3M | ENGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENGN REV | TVGN REV | ENGN GROSS % | TVGN GROSS % | ENGN FCF | TVGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$100.7M | -$12.4M |
| FY 2024 | $0 | $0 | — | — | -$49.2M | -$12.0M |
| FY 2023 | $0 | $0 | — | — | -$24.7M | -$8.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENGN // BETA —
TVGN // BETA —